Partnership targets heart failure, the leading cause of death and a condition with limited treatment options BioCardia's biotherapeutic delivery system with established safety profile enables minimally invasive transplantation of StemCardia's off-the-shelf cardiac muscle cells SUNNYVALE, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders, and StemCardia, Inc., a biotechnolog ...